Skip to main content
About
Contact
Subscribe
e-Edition
Make Home Page
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Twitter
Toggle navigation
Site search
Search
Home
Contact Us
Advertise
Subscription Services
Promote Your Event
Submission Forms
News
Local News
National
World
Archives
Sports
Local Sports
National Sports
Business
Local Business
National Business
Technology
Markets & Stocks
Opinion
Columns
Editorials
Letters To The Editor
Polls
Thumbs
A & E
Local Entertainment
Art Scene
Music Scene
Theatre Scene
Book Reviews
Movie Reviews
TV Listings
Local Events
What To Do
Life
Health
Travel
Oddities
Community Directory
Community Service
Rescue Me
Other
Specials
Spring Home & Garden Show
Home & Realty
Outdoor Guide
Women
Spring on the Road
Spring Wellness
Premier Home Stylle Tour 2024
Classifieds
Place Ad
Careers
Tenders
Weather
Obituaries
2024 Auction
2024 Readersâ Choice Awards
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by MaxCyte, Inc
MaxCyte to Report First Quarter 2024 Financial Results on May 7, 2024
April 10, 2024
From
MaxCyte, Inc
Via
GlobeNewswire
Tickers
MXCT
MaxCyte Signs Strategic Platform License with Be Biopharma to Support the Development of Engineered B Cell Medicines (BCMs)
April 02, 2024
From
MaxCyte, Inc
Via
GlobeNewswire
Tickers
MXCT
MaxCyte Reports Fourth Quarter and Full Year 2023 Financial Results and Reiterates 2024 Guidance
March 12, 2024
From
MaxCyte, Inc
Via
GlobeNewswire
Tickers
MXCT
MaxCyte Initiates Full Year 2024 Guidance and Reaffirms 2023 Preliminary Results
March 04, 2024
From
MaxCyte, Inc
Via
GlobeNewswire
Tickers
MXCT
MaxCyte to Report Fourth Quarter and Full Year 2023 Financial Results on March 12, 2024 and Participate in Upcoming Investor Conferences
February 09, 2024
From
MaxCyte, Inc
Via
GlobeNewswire
Tickers
MXCT
MaxCyte and Wugen Sign Strategic Platform License to Expedite Scale-Up of Clinical and Commercial Manufacturing of Wugen’s Investigational Allogeneic, Off-the-Shelf Cell Therapies for Cancers
January 30, 2024
From
MaxCyte, Inc
Via
GlobeNewswire
Tickers
MXCT
MaxCyte Signs Strategic Platform License with Imugene to Advance their Cancer Immunotherapy Programs
January 23, 2024
From
MaxCyte, Inc
Via
GlobeNewswire
Tickers
ASX:IMU
MXCT
MaxCyte Announces Preliminary Unaudited Fourth Quarter and Full Year 2023 Financial Results
January 08, 2024
From
MaxCyte, Inc
Via
GlobeNewswire
Tickers
MXCT
MaxCyte Confirms Appointment of Maher Masoud as President, Chief Executive Officer and Director
January 02, 2024
From
MaxCyte, Inc
Via
GlobeNewswire
Tickers
MXCT
MaxCyte Announces CEO Transition and Updates Revenue Guidance for 2023
December 11, 2023
From
MaxCyte, Inc
Via
GlobeNewswire
Tickers
MXCT
MaxCyte Joins the Alliance for mRNA Medicines (AMM) as a Founding Member
November 16, 2023
From
MaxCyte, Inc
Via
GlobeNewswire
Tickers
MXCT
MaxCyte Reports Third Quarter 2023 Financial Results and Reiterates Full Year 2023 Revenue Guidance
November 08, 2023
From
MaxCyte, Inc
Via
GlobeNewswire
Tickers
MXCT
MaxCyte to Participate in Two Upcoming Investor Conferences
November 06, 2023
From
MaxCyte, Inc
Via
GlobeNewswire
Tickers
MXCT
MaxCyte Announces Preliminary Third Quarter 2023 Revenue and Updates Full Year 2023 Revenue Guidance
October 04, 2023
From
MaxCyte, Inc
Via
GlobeNewswire
Tickers
MXCT
MaxCyte Appoints Ali Soleymannezhad as Executive Vice President of Bioprocessing
September 06, 2023
From
MaxCyte, Inc
Via
GlobeNewswire
Tickers
MXCT
MaxCyte to Participate in Baird Global Healthcare Conference
September 05, 2023
From
MaxCyte, Inc
Via
GlobeNewswire
Tickers
MXCT
MaxCyte Reports Second Quarter and Half-Year 2023 Financial Results and Updates Full Year 2023 Guidance
August 09, 2023
From
MaxCyte, Inc
Via
GlobeNewswire
Tickers
MXCT
MaxCyte Signs Strategic Platform License with Prime Medicine to Advance Next-Generation Gene Editing Therapies for Patients
August 01, 2023
From
MaxCyte, Inc
Via
GlobeNewswire
Tickers
MXCT
MaxCyte to Report Second Quarter 2023 Financial Results on August 9, 2023
July 13, 2023
From
MaxCyte, Inc
Via
GlobeNewswire
Tickers
MXCT
MaxCyte and Vittoria Biotherapeutics Sign Strategic Platform License to Advance Next Generation Cellular Therapies
July 10, 2023
From
MaxCyte, Inc
Via
GlobeNewswire
Tickers
MXCT
MaxCyte Signs Strategic Platform License with Lyell Immunopharma
July 06, 2023
From
MaxCyte, Inc
Via
GlobeNewswire
Tickers
MXCT
MaxCyte to Participate in Upcoming Investor Conferences
June 01, 2023
From
MaxCyte, Inc
Via
GlobeNewswire
Tickers
MXCT
MaxCyte Reports First Quarter 2023 Financial Results and Updates Full Year 2023 Guidance
May 10, 2023
From
MaxCyte, Inc
Via
GlobeNewswire
Tickers
MXCT
MaxCyte Signs Strategic Platform License with Walking Fish Therapeutics to Support the Development of its Innovative B Cell Platform
May 04, 2023
From
MaxCyte, Inc
Via
GlobeNewswire
Tickers
MXCT
MaxCyte to Report First Quarter 2023 Financial Results on May 10, 2023
April 12, 2023
From
MaxCyte, Inc
Via
GlobeNewswire
Tickers
MXCT
MaxCyte Appoints Douglas Swirsky as Chief Financial Officer
March 27, 2023
From
MaxCyte, Inc
Via
GlobeNewswire
Tickers
MXCT
MaxCyte Reports Fourth Quarter and Full Year 2022 Financial Results
March 15, 2023
From
MaxCyte, Inc
Via
GlobeNewswire
Tickers
MXCT
MaxCyte Establishes New Scientific Advisory Board Comprised of Globally Recognized Experts in Cell Engineering Enabling Technology
March 08, 2023
From
MaxCyte, Inc
Via
GlobeNewswire
Tickers
MXCT
MaxCyte Announces Preliminary Unaudited Fourth Quarter and Full Year 2022 Revenue Results and Provides 2023 Revenue Guidance
March 06, 2023
From
MaxCyte, Inc
Via
GlobeNewswire
Tickers
MXCT
MaxCyte to Report Fourth Quarter and Full Year 2022 Financial Results on March 15, 2023 and Participate in Upcoming Investor Conferences
February 01, 2023
From
MaxCyte, Inc
Via
GlobeNewswire
Tickers
MXCT
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.